Mankind Pharma Limited – Investor Presentation Summary

Key Operational Highlights

  • FY26 revenue: ₹14,278 Crore with 18.1% CAGR from FY21–26
  • Market leadership: #1 prescription rank for 9 years, #4 IPM rank by value
  • Commercial reach: 5 lakh+ doctors covered, 18,500+ field force, 17,600+ stockists nationwide, 84% prescriber penetration
  • Manufacturing transformation: Moved from third-party to ~75% in-house production
  • Key operational drivers: New product launches, geographic expansion, manufacturing integration, and consumer healthcare scaling

Segment-wise Performance

  • Consumer Healthcare segment: ₹879 Crore FY26 revenue with 4 brands ranked #1 in their categories
  • E-commerce share growth: 4% in FY25 → 8% in FY26 → 14% in Q2 FY27
  • Brand performance: 22 brand families > ₹100 Crore, 54 brands > ₹50 Crore
  • Large brand growth: Telmikind ₹783 Cr (20% FY26 growth), Nurokind ₹667 Cr (8% growth), Manforce ₹647 Cr (12% growth)

Financial Highlights

  • Revenue: ₹14,278 Crore (FY26)
  • Strong financial discipline with prudent capital allocation
  • Comparison: 18.1% revenue CAGR from FY21–26 demonstrates consistent growth trajectory

Strategic & R&D Initiatives

  • Manufacturing investments: Udaipur Facility (EU GMP Certified, India's 1st fully integrated Dydrogesterone plant)
  • Future capacity: Vadodara biologics plant underway for complex biologics (FY27–28)
  • Recent successful launches: Vonalong (Vonoprazan, #1 rank, 12% share), Nurokind HS PFS (Mecobalamin, #2 rank, 12% share), AdvaUD (Nor-Ursodeoxycholic Acid, #2 rank, 36% share), DynaDuo (Empagliflozin + Linagliptin, #4 rank, 5% share)
  • Upcoming major launches: Resmetirom (NASH – fatty liver disease), Insulin Aspart & Degludec (Diabetes – insulin franchise), Perfluoro-hexyloctane (Dry eye disease), Latanoprostene bunod (Glaucoma), Ensifentrine (COPD)

Consumer Healthcare Strategy

  • Leadership in sexual wellness: Manforce condoms (28% share), Unwanted emergency contraceptives (68% share)
  • Pregnancy care: Prega News pregnancy test kits (83% share), extended into Ova News
  • Consumer wellness expansion: Gas-O-Fast antacid powder (11% share), Acne Star medicated anti-acne (33% share)
  • Growth strategy: Scale consumer healthcare, accelerate presence in new-age channels, premiumize product portfolio, expand into new wellness categories

Strategic Acquisition – Armed Cell Therapeutics

  • Acquisition of ACTx for next-generation CAR-T cell therapy
  • Leadership team: Paul Stoffels (Founder and Chair, former CSO and Vice Chair of J&J), Prof. John Mellors (Chief Scientific Officer), Peter Verhaeghe (Board member), Willemijn Kremer (CEO)
  • Strategic focus: In vivo CAR-T delivery to make treatment scalable, faster and accessible
  • Two lead programs: Non-Hodgkin lymphoma and small cell lung cancer
  • Technology advantage: Combines ex vivo and in vivo approaches in next generation CAR-T

Industry Trends & Business Environment

  • Cancer treatment evolution: Rising precision, efficacy and value in cancer therapeutics
  • CAR-T advantages: Single infusion instead of continuous treatment, deep responses with highest response rates, durable remissions lasting years
  • Market validation: Large pharma investing significantly in in vivo CAR-T, validating strategic direction

Management Commentary & Growth Outlook

  • Strategic outlook: "Outperform IPM" growth target
  • Growth pillars: Chronic & Specialty, Consumer Healthcare, BSV – High-Barrier Specialty
  • Capital allocation: Prudent allocation led by financial discipline
  • Expansion strategy: Rx → OTx → OTC switch for proven Rx brands to consumer channels